摘要
目的探讨紫杉醇脂质体与表柔比星联合应用于晚期乳腺癌中的效果及对乳腺癌缺失基因1(DBC1)与沉默信息调节因子1(SIRT1)的影响。方法选择2019年5月—2020年5月该院收治的晚期乳腺癌患者98例,以随机数字表法进行分组,其中对照组与研究组各49例。对照组采用表柔比星联合多西他赛治疗,研究组应用紫杉醇脂质体联合表柔比星治疗。对比两组化疗治疗效果、治疗前后SIRT1与DBC1的阳性表达指数、不良反应情况。结果研究组化疗治疗的总有效率91.84%高于对照组73.47%,差异有统计学意义(χ^(2)=5.765,P<0.05)。治疗后,研究组SIRT1、DBC1的阳性表达指数(3.7±0.8)分、(3.5±0.5)分低于对照组(4.9±0.5)分、(4.8±0.8)分,差异有统计学意义(t=8.904,9.646,P<0.05)。研究组化疗期间消化系统、皮疹不良反应的发生率16.33%、4.08%低于对照组53.06%、24.49%,差异有统计学意义(χ^(2)=14.592,8.333,P<0.05)。结论紫杉醇脂质体与表柔比星联合应用于晚期乳腺癌中具有显著的效果,并可以改善DBC1与SIRT1,降低不良反应概率。
Objective To investigate the effect of paclitaxel liposome and epirubicin combined in advanced breast cancer and its effect on breast cancer deletion gene 1(DBC1)and silent information regulator 1(SIRT1).Methods A total of 98 patients with advanced breast cancer who were admitted to the hospital from May 2019 to May 2020 were selected and grouped by random number table method,of which 49 cases were in the control group and 49 cases in the study group.The control group was treated with epirubicin combined with docetaxel,and the study group was treated with paclitaxel liposomes combined with epirubicin.The effects of chemotherapy,the positive expression index of SIRT1 and DBC1 before and after treatment,and adverse reactions were compared between the two groups.Results The total effective rate of chemotherapy in the study group was 91.84%higher than that of the control group 73.47%,the difference was statistically significant(χ^(2)=5.765,P<0.05).After treatment,the positive expression index of SIRT1 and DBC1 in the study group(3.7±0.8)points and(3.5±0.5)points were lower than those of the control group(4.9±0.5)points and(4.8±0.8)points,the difference was statistically significant(t=8.904,9.646,P<0.05).The incidence of adverse reactions of the digestive system and skin rash during chemotherapy in the study group was 16.33%and 4.08%lower than that of the control group 53.06%and 24.49%,the difference was statistically significant(χ^(2)=14.592,8.333,P<0.05).Conclusion The combination of paclitaxel liposome and epirubicin has a significant effect in advanced breast cancer,and can improve DBC1 and SIRT1 and reduce the probability of adverse reactions.
作者
方亮
FANG Liang(Department of Oncology,Central Hospital of Shandong Xinwen Mining Group Co.,Ltd.,Xintai,Shandong Province,271219 China)
出处
《世界复合医学》
2021年第5期163-165,194,共4页
World Journal of Complex Medicine
